» Articles » PMID: 24557705

Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases

Overview
Specialty Neurology
Date 2014 Feb 22
PMID 24557705
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: IDH1 mutational status probably plays an important role in the predictive response for patients with astroglioma. This study explores whether DTI metrics are able to noninvasively detect IDH1 status in astrogliomas.

Materials And Methods: The DTI data of 112 patients with pathologically proven astroglioma (including 25, 12, and 10 cases with IDH1 mutation and 11, 11, and 43 cases without mutation in grades II, III, and IV, respectively) were retrospectively reviewed. The maximal fractional anisotropy, minimal ADC, ratio of maximal fractional anisotropy, and ratio of minimal ADC in the tumor body were measured. In the same World Health Organization grading, the imaging parameters of patients with and without IDH1 R132H mutation were compared by means of optimal metrics for detecting mutations. Receiver operating characteristic curve analysis was performed.

Results: The maximal fractional anisotropy and ratio of maximal fractional anisotropy values had statistical significance between patients with IDH1 R132H mutation and those without mutation in astrogliomas of grades II and III. The areas under the curve for maximal fractional anisotropy and ratio of maximal fractional anisotropy were both 0.92 in grade II and 0.80 and 0.82 in grade III. The minimal ADC value and ratio of minimal ADC value also demonstrated statistical significance between patients with mutation and those without mutation in all astroglioma grades. The areas under the curve for minimal ADC were 0.94 (II), 0.76 (III), and 0.66 (IV), and the areas under the curve for ratio of minimal ADC were 0.93 (II), 0.83 (III), and 0.70 (IV).

Conclusions: Fractional anisotropy and ADC from DTI can noninvasively detect IDH1 R132H mutation in astrogliomas.

Citing Articles

Research Progress on Glioma Microenvironment and Invasiveness Utilizing Advanced Multi-Parametric Quantitative MRI.

Song D, Fan G, Chang M Cancers (Basel). 2025; 17(1.

PMID: 39796702 PMC: 11719598. DOI: 10.3390/cancers17010074.


IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications.

Choate K, Pratt E, Jennings M, Winn R, Mann P Biology (Basel). 2024; 13(11).

PMID: 39596840 PMC: 11592129. DOI: 10.3390/biology13110885.


MRI-based radiogenomics analysis for predicting prognosis and XRCC1 gene polymorphism in pancreatic ductal adenocarcinoma.

Goktas M, Karabulut D, Unlu A, Achmet G, Tuncbilek N Clin Transl Oncol. 2024; .

PMID: 39487951 DOI: 10.1007/s12094-024-03763-3.


Study on the Relationship Between MRI Functional Imaging and Multiple Immunohistochemical Features of Glioma: A Noninvasive and More Precise Glioma Management.

Li J, Sun J, Wang N, Zhang Y Mol Imaging. 2024; 23:15353508241261583.

PMID: 38952400 PMC: 11208885. DOI: 10.1177/15353508241261583.


Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.

Yuan J, Siakallis L, Li H, Brandner S, Zhang J, Li C BMC Med Imaging. 2024; 24(1):104.

PMID: 38702613 PMC: 11067215. DOI: 10.1186/s12880-024-01274-9.


References
1.
Loussouarn D, Le Loupp A, Frenel J, Leclair F, von Deimling A, Aumont M . Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol. 2012; 40(6):2058-62. DOI: 10.3892/ijo.2012.1404. View

2.
Khayal I, VandenBerg S, Smith K, Cloyd C, Chang S, Cha S . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol. 2011; 13(11):1192-201. PMC: 3199150. DOI: 10.1093/neuonc/nor122. View

3.
Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

4.
Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

5.
Jakab A, Molnar P, Emri M, Berenyi E . Glioma grade assessment by using histogram analysis of diffusion tensor imaging-derived maps. Neuroradiology. 2010; 53(7):483-91. DOI: 10.1007/s00234-010-0769-3. View